Adaptive Biotechnologies develops a platform technology that analyzes the adaptive immune system using proprietary chemistry, computational methods, and machine learning to generate immunomics data for diagnostic and therapeutic applications. The company's primary offering is clonoSEQ, a test that identifies and tracks residual cancer cells in patients undergoing or following treatment. Its technology serves applications across life sciences research, clinical diagnostics, and drug development.

entry readiness 9 · NOT READY · exit proximity 15

Value area 19.80–29.65 · 18% of 120d volume overhead · clean runway